8,925 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,925 shares of the biopharmaceutical company’s stock, valued at approximately $539,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in XENE. Seven Fleet Capital Management LP purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter worth $2,084,000. Corient Private Wealth LP purchased a new position in Xenon Pharmaceuticals in the second quarter valued at $1,734,000. Artia Global Partners LP acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth $3,923,000. Bamco Inc. NY acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth $1,509,000. Finally, Bank of America Corp DE acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth $24,389,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $59.99 on Friday. The company’s fifty day moving average price is $63.18 and its 200 day moving average price is $56.39. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The firm has a market capitalization of $5.80 billion, a P/E ratio of -12.66 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the firm earned ($1.07) earnings per share. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director directly owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,512 shares of company stock valued at $774,088 in the last quarter. 2.91% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on XENE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reissued a “buy” rating and set a $74.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, August 10th. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $77.13.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.